公开(公告)号：US20200297474A1

公开(公告)日：2020-09-24

申请号：US16753567

申请日：2018-10-05

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： Chao-Wei Hwang ,  Peter Johnston ,  Gary Gerstenblith ,  Robert G. Weiss ,  Gordon Tomaselli ,  Steven Schulman

IPC: A61F2/02 ,  A61K47/38 ,  A61K35/28 ,  A61K9/16 ,  A61K35/33 ,  A61K47/34 ,  A61M39/02 ,  A61K47/36 ,  A61K38/39 ,  A61K9/06 ,  A61L29/16 ,  A61L27/54 ,  A61L27/52 ,  A61L27/56 ,  A61L27/48 ,  A61L27/38 ,  A61L27/34 ,  A61L27/26

Abstract: The present invention provides an implantable bioreactor comprising cells enclosed within an enclosure, said cells being capable of producing paracrine factors, wherein the enclosure is collapsible or expandable or both or neither, wherein the enclosure is semipermeable such that it provides containment of the cells preventing the egress of the cells while further providing a barrier that shields the cells from immunological attack, and wherein the enclosure is permeable to the entire secretome of the cell including exosomes, nucleic acids and proteins. The implantable bioreactor can have various configurations and can house internally a cell culture matrix than can include hydrogels, microbeads, and nanofiber matrices along with other active agents.

公开(公告)号：US20170245976A1

公开(公告)日：2017-08-31

申请号：US15467455

申请日：2017-03-23

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： Gary Gerstenblith ,  Jason Benkoski ,  Jeffrey Brinker ,  George Coles ,  Chao-Wei Hwang ,  Peter Johnston ,  Gordon Tomaselli ,  Robert G. Weiss ,  Steven P. Schulman

IPC: A61F2/02 ,  A61L27/56 ,  A61K35/545 ,  A61L27/28 ,  A61L27/54 ,  A61L27/16 ,  A61L27/38 ,  A61L29/00

CPC classification number: A61F2/022 ,  A61K35/28 ,  A61K35/545 ,  A61L27/16 ,  A61L27/28 ,  A61L27/3834 ,  A61L27/54 ,  A61L27/56 ,  A61L29/00 ,  A61L29/005 ,  A61L29/16 ,  A61L2300/42 ,  A61L2300/64 ,  A61L2430/20 ,  C12N5/0663 ,  C12N2533/30

Abstract: An implantable bioreactor containing a barrier which is designed to allow the release of cell-derived biomolecules, but restricts the entry of immunologic and other cells, or the egress of the cells contained within the bioreactor. Two broad classes of implantable bioreactors are envisioned, encompassing devices for both systemic delivery of the bio-products and local delivery at the target tissue. Bioreactors of both classes can be implanted via surgery, through percutaneous techniques, or other techniques which effect implantation.

公开(公告)号：US20190314416A1

公开(公告)日：2019-10-17

申请号：US16281620

申请日：2019-02-21

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： Gary Gerstenblith ,  Jason Benkoski ,  George Coles ,  Chao-Wei Hwang ,  Peter Johnston ,  Gordon Tomaselli ,  Robert G. Weiss ,  Steven P. Schulman

IPC: A61K35/28 ,  A61L31/14 ,  A61L31/10 ,  A61K9/00 ,  A61L29/14 ,  A61L29/16 ,  A61L31/16

Abstract: A method for promoting healing of tissue by delivering a bioreactor into a subject is provided. The bioreactor is an enclosed housing with paracrine factor producing cells enclosed within the housing. The housing is impermeable to the paracrine factor producing cells, impermeable to immunological cells outside of the housing, and permeable to paracrine factors produced by the paracrine factor producing cells. The paracrine factors produced by the paracrine factor producing cells are released out of the housing to promote healing of the tissue.

公开(公告)号：US20180160917A1

公开(公告)日：2018-06-14

申请号：US15571771

申请日：2016-05-05

Applicant: The Johns Hopkins University ,  Boston Scientific Scimed Inc.

Inventor： Qian Liu ,  Nichaluk Leartprapun ,  Jackline Wanjala ,  Soumyadipta Acharya ,  Andrew Bicek ,  Viachaslau Barodka ,  Umang Anand ,  Majd Alghatrif ,  David Kass ,  B. Westbrook Bernier ,  Chao-Wei Hwang ,  Peter Johnston ,  Trent Langston

IPC: A61B5/021 ,  A61B5/053 ,  A61B5/00

Abstract: The present application relates to systems and methods for non-invasively determining at least one of left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) in a subject's heart, comprising: receiving, by a computer, a plurality of signals from a plurality of non-invasive sensors that measure a plurality of physiological effects that are correlated with functioning of said subject's heart, said plurality of physiological effects including at least one signal correlated with left ventricular blood pressure and at least one signal correlated with timing of heartbeat cycles of said subject's heart; training a machine learning model on said computer using said plurality of signals for periods of time in which said plurality of signals were being generated during a heart failure event of said subject's heart; determining said LVEDP or PCWP using said machine learning model at a time subsequent to said training and subsequent to said heart failure event.

公开(公告)号：US10772716B2

公开(公告)日：2020-09-15

申请号：US16281620

申请日：2019-02-21

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： Gary Gerstenblith ,  Jason Benkoski ,  George Coles ,  Chao-Wei Hwang ,  Peter Johnston ,  Gordon Tomaselli ,  Robert G. Weiss ,  Steven P. Schulman ,  Jeffrey A. Brinker

IPC: A61F2/02 ,  A61L27/38 ,  A61L27/54 ,  A61K35/545 ,  A61L29/00 ,  A61L29/16 ,  C12N5/0775 ,  A61K35/28 ,  A61K9/00 ,  A61L29/14 ,  A61L31/10 ,  A61L31/14 ,  A61L31/16 ,  A61L27/16 ,  A61L27/28 ,  A61L27/56

Abstract: A method for promoting healing of tissue by delivering a bioreactor into a subject is provided. The bioreactor is an enclosed housing with paracrine factor producing cells enclosed within the housing. The housing is impermeable to the paracrine factor producing cells, impermeable to immunological cells outside of the housing, and permeable to paracrine factors produced by the paracrine factor producing cells. The paracrine factors produced by the paracrine factor producing cells are released out of the housing to promote healing of the tissue.

公开(公告)号：US10729337B2

公开(公告)日：2020-08-04

申请号：US15571771

申请日：2016-05-05

Applicant: The Johns Hopkins University ,  Boston Scientific Scimed Inc.

Inventor： Qian Liu ,  Nichaluk Leartprapun ,  Jackline Wanjala ,  Soumyadipta Acharya ,  Andrew Bicek ,  Viachaslau Barodka ,  Umang Anand ,  Majd Alghatrif ,  David Kass ,  B. Westbrook Bernier ,  Chao-Wei Hwang ,  Peter Johnston ,  Trent Langston

IPC: A61B5/021 ,  A61B5/00 ,  A61B5/053 ,  A61B5/0452

Abstract: The present application relates to systems and methods for non-invasively determining at least one of left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) in a subject's heart, comprising: receiving, by a computer, a plurality of signals from a plurality of non-invasive sensors that measure a plurality of physiological effects that are correlated with functioning of said subject's heart, said plurality of physiological effects including at least one signal correlated with left ventricular blood pressure and at least one signal correlated with timing of heartbeat cycles of said subject's heart; training a machine learning model on said computer using said plurality of signals for periods of time in which said plurality of signals were being generated during a heart failure event of said subject's heart; determining said LVEDP or PCWP using said machine learning model at a time subsequent to said training and subsequent to said heart failure event.